Investigadores
Inicio
Investigadores
Hospital Universitario Virgen del Rocio (HUVR). Sevilla.
Inmunoterapia Celular (células CAR)
Terapia de células somáticas y medicina regenerativa
JOSÉ ANTONIO PÉREZ SIMÓN
Investigador principal
Grupo de Investigación: Hospital Universitario Virgen del Rocio (HUVR). Sevilla.
Belén Sierro Martínez
Investigador colaborador
Grupo de Investigación: Hospital Universitario Virgen del Rocio (HUVR). Sevilla.
ELENA DE LA TORRE MADRID
Investigador colaborador
Grupo de Investigación: Hospital Universitario Virgen del Rocio (HUVR). Sevilla.
Estefania Garcia Guerrero
Investigador colaborador
Grupo de Investigación: Hospital Universitario Virgen del Rocio (HUVR). Sevilla.
Maribel Lara Chica
Investigador colaborador
Grupo de Investigación: Hospital Universitario Virgen del Rocio (HUVR). Sevilla.
Teresa Caballero Velázquez
Investigador colaborador
Grupo de Investigación: Hospital Universitario Virgen del Rocio (HUVR). Sevilla.
VIRGINIA ESCAMILLA GÓMEZ
Investigador colaborador
Grupo de Investigación: Hospital Universitario Virgen del Rocio (HUVR). Sevilla.
Martínez-Rubio Á., Chulián S., Niño-López A., Picón-González R., Rodríguez Gutiérrez J.F., Gálvez de la Villa E., Caballero Velázquez T., Molinos Quintana Á., Castillo Robleda A., Ramírez Orellana M., Martínez Sánchez M.V., Minguela Puras A., Fuster Soler J.L., Blázquez Goñi C., Pérez-García V.M., Rosa M.. Computational flow cytometry immunophenotyping at diagnosis is unable to predict relapse in childhood B-cell Acute Lymphoblastic Leukemia. Computers in Biology and Medicine. April 2025. DOI: 10.1016/j.compbiomed.2025.109831.
Impacto: 7.0. Cuartil: Q1
(1er decil)
Rodríguez-Arbolí E., Rodríguez-Veiga R., Soria-Saldise E., Bergua J.M., Caballero-Velázquez T., Arnán M., Vives S., Serrano J., Bernal T., Martínez-Sánchez P., Tormo M., Rodríguez-Medina C., Herrera-Puente P., Lavilla-Rubira E., Boluda B., Acuña-Cruz E., Cano I., Cáceres S., Ballesteros J., Falantes J., Martínez-Cuadrón D., Pérez-Simón J.A., Montesinos P.. A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX. Cancer. 1 January 2025. DOI: 10.1002/cncr.35618.
Impacto: 6.1. Cuartil: Q1
Marrero-Cepeda C., Caballero-Velazquez T., Garcia-Canale S., Martin-Dominguez F., Rodriguez-Torres N., Espigado-Tocino I., Blazquez-Goñi C., Andrade-Ruiz H., Perez-Simon J.. Monocytosis as prognostic factor for chronic graft versus host disease. Bone Marrow Transplantation. September 2024. DOI: 10.1038/s41409-024-02333-z.
Impacto: 4.5. Cuartil: Q1
Avendaño M.S., Perdices-Lopez C., Guerrero-Ruiz Y., Ruiz-Pino F., Rodriguez-Sanchez A.B., Sanchez-Tapia M.J., Sobrino V., Pineda R., Barroso A., Correa-Sáez A., Lara-Chica M., Fernandez-Garcia J.C., García-Redondo A.B., Hernanz R., Ruiz-Cruz M., Garcia-Galiano D., Pitteloud N., Calzado M.A., Briones A.M., Vázquez M.J., Tena-Sempere M.. The evolutionary conserved miR-137/325 tandem mediates obesity-induced hypogonadism and metabolic comorbidities by repressing hypothalamic kisspeptin. Metabolism: Clinical and Experimental. August 2024. DOI: 10.1016/j.metabol.2024.155932.
Impacto: 10.8. Cuartil: Q1
(1er decil)
Medrano M., Contreras M., Caballero-Velázquez T., Martínez L., Bejarano-García J.A., Calderón-Ruiz R., García-Calderón C.B., Rosado I.V., Pérez-Simón J.A.. Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions. British Journal of Cancer. 18 May 2024. DOI: 10.1038/s41416-024-02618-6.
Impacto: 6.4. Cuartil: Q1
Guijarro-Albaladejo B., Marrero-Cepeda C., Rodríguez-Arbolí E., Sierro-Martínez B., Pérez-Simón J.A., García-Guerrero E.. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations. Frontiers in Cell and Developmental Biology. 2024. DOI: 10.3389/fcell.2024.1376554.
Impacto: 4.6. Cuartil: Q1
Molinos-Quintana Á., Alonso-Saladrigues A., Herrero B., Caballero-Velázquez T., Galán-Gómez V., Panesso M., Torrebadell M., Delgado-Serrano J., Pérez de Soto C., Faura A., González-Martínez B., Castillo-Robleda A., Diaz-de-Heredia C., Pérez-Martínez A., Pérez-Hurtado J.M., Rives S., Pérez-Simón J.A.. Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring (Front. Immunol., (2024), 14, 1280580, 10.3389/fimmu.2023.1280580). Frontiers in Immunology. 2024. DOI: 10.3389/fimmu.2024.1373852.
Impacto: 5.7. Cuartil: Q1
Escamilla-Gómez V., García Gutiérrez V., Alcalde-Mellado P., Astibia-Mahillo B., Chinea-Rodriguez A., López-Corral L., Acera-Gómez M., Torres Ochando M.K., Borrero Borrego A., González Pinedo L., Zudaire Ripa T., González Vicent M., Benzaquén A., Izquierdo Garcia I., Asensi Cantó P., Montoro J., Martín-Domínguez F.M., Orti G., Valcárcel D., Benitez-Carabante M.I., Diaz-de-Heredia C., Cañamero E., Ferrá C., García-Cadenas I., Redondo S., Sisinni L., Perez-Martínez A., Mussetti A., Garcia-Mañó L., Palomo-Moraleda M.D.P., González-Sierra P.A., Jurado M., Perez-Simon J.A., Chacón M.J., Maño L.G., Martínez A.P., Carabante M.I.B., Domínguez F.M.M., Cantó P.A., Garcia I.I., Vallejos A.B.. Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC. Bone Marrow Transplantation. 2024. DOI: 10.1038/s41409-024-02483-0.
Impacto: 4.5. Cuartil: Q1
Morales-Camacho R.M., Caballero-Velázquez T., Borrero J.J., Bernal R., Prats-Martín C.. Hematological Neoplasms with Eosinophilia. Cancers. January 2024. DOI: 10.3390/cancers16020337.
Impacto: 4.5. Cuartil: Q1
Sierro-Martínez B., Escamilla-Gómez V., Pérez-Ortega L., Guijarro-Albaladejo B., Hernández-Díaz P., de la Rosa-Garrido M., Lara-Chica M., Rodríguez-Gil A., Reguera-Ortega J.L., Sanoja-Flores L., Arribas-Arribas B., Montiel-Aguilera M.Á., Carmona G., Robles M.J., Caballero-Velázquez T., Briones J., Einsele H., Hudecek M., Pérez-Simón J.A., García-Guerrero E.. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. Cellular Oncology. 2024. DOI: 10.1007/s13402-024-00984-0.
Impacto: 4.9. Cuartil: Q1
Ramos F., Hermosín M.L., Fuertes-Núñez M., Martínez P., Rodriguez-Medina C., Barrios M., Ibáñez F., Bernal T., Olave M.T., Álvarez M.Á., Vahí M., Caballero-Velázquez T., González B., Altés A., García L., Fernández P., Durán M.A., López R., Rafel M., Serrano J.. Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice. Journal of Personalized Medicine. December 2023. DOI: 10.3390/jpm13121667.
Impacto: 3.0. Cuartil: Q1
Rodríguez-Arbolí E., Lee C.J., Caballero-Velázquez T., Martínez C., García-Calderón C., Jiménez-León M.R., Bermúdez-Rodríguez M.A., López-Corral L., Triguero A., Onstad L., Horwitz M.E., Sarantopoulos S., Lee S.J., Pérez-Simón J.A.. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials. Clinical Cancer Research. 15 October 2023. DOI: 10.1158/1078-0432.CCR-23-0666.
Impacto: 10.0. Cuartil: Q1
Caballero-Velázquez T., Pérez-López O., Yeguas Bermejo A., Rodríguez Arbolí E., Colado Varela E., Sempere Talens A., Vidriales M.B., Solé-Rodríguez M., Quirós Caso C., Pérez López E., Reinoso Segura M., Prats-Martín C., Montesinos P., Pérez-Simón J.A.. Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study. Cancers. March 2023. DOI: 10.3390/cancers15051609.
Impacto: 4.5. Cuartil: Q1
García-Guerrero E., Rodríguez-Lobato L.G., Sierro-Martínez B., Danhof S., Bates S., Frenz S., Haertle L., Götz R., Sauer M., Rasche L., Kortüm K.M., Pérez-Simón J.A., Einsele H., Hudecek M., Prommersberger S.R.. All-trans retinoic acid works synergistically with the γsecretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica. February 2023. DOI: 10.3324/haematol.2022.281339.
Impacto: 8.2. Cuartil: Q1
Moniche F., Cabezas-Rodriguez J.A., Valverde R., Escudero-Martinez I., Lebrato-Hernandez L., Pardo-Galiana B., Ainz L., Medina-Rodriguez M., de la Torre J., Escamilla-Gomez V., Ortega-Quintanilla J., Zapata-Arriaza E., de Albóniga-Chindurza A., Mancha F., Gamero M.A., Perez S., Espinosa-Rosso R., Forero-Diaz L., Moya M., Piñero P., Calderón-Cabrera C., Nogueras S., Jimenez R., Martin V., Delgado F., Ochoa-Sepúlveda J.J., Quijano B., Mata R., Santos-González M., Carmona-Sanchez G., Herrera C., Gonzalez A., Montaner J.. Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial. The Lancet Neurology. February 2023. DOI: 10.1016/S1474-4422(22)00526-9.
Impacto: 46.5. Cuartil: Q1
(1er decil)
Molinos-Quintana Á., Alonso-Saladrigues A., Herrero B., Caballero-Velázquez T., Galán-Gómez V., Panesso M., Torrebadell M., Delgado-Serrano J., Pérez de Soto C., Faura A., González-Martínez B., Castillo-Robleda A., Diaz-de-Heredia C., Pérez-Martínez A., Pérez-Hurtado J.M., Rives S., Pérez-Simón J.A.. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1280580.
Impacto: 5.7. Cuartil: Q1
García-Calderón C.B., Sierro-Martínez B., García-Guerrero E., Sanoja-Flores L., Muñoz-García R., Ruiz-Maldonado V., Jimenez-Leon M.R., Delgado-Serrano J., Molinos-Quintana Á., Guijarro-Albaladejo B., Carrasco-Brocal I., Lucena J.M., García-Lozano J.R., Blázquez-Goñi C., Reguera-Ortega J.L., González-Escribano M.F., Reinoso-Segura M., Briones J., Pérez-Simón J.A., Caballero-Velázquez T.. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Frontiers in Immunology. 2023. DOI: 10.3389/fimmu.2023.1152498.
Impacto: 5.7. Cuartil: Q1
Rodríguez-Gil A., Escamilla-Gómez V., Nufer M., Andújar-Sánchez F., Lopes-Ramos T., Bejarano-García J.A., García-Guerrero E., Calderón-Cabrera C., Caballero-Velázquez T., García-Calderón C.B., Hernández-Díaz P., Reguera-Ortega J.L., Rodríguez-Torres N., Martínez-Cibrián N., Rodríguez-Barbosa J.I., Villadiego J., Pérez-Simón J.A.. Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib. Scientific Reports. December 2022. DOI: 10.1038/s41598-022-12407-x.
Impacto: 4.6. Cuartil: Q2
Mellado-Gázquez Á., Gómez-Núñez M.R., Jurado-Herrera S., Prats-Martín C., Caballero-Velázquez T., Morales-Camacho R.M.. Multiple erythrophagocytosis by erythroid blasts in acute myeloid leukemia with BCR-ABL1. Annals of Hematology. June 2022. DOI: 10.1007/s00277-021-04742-2.
Impacto: 3.5. Cuartil: Q2
Reinoso-Segura M., Caballero-Velázquez T., Herrera P., Patriarca F., Fanin R., Bruno B., Einsele H., Nahi H., Granell M., López-Corral L., Reguera J.L., García-Cadenas I., Gahrton G., Pérez-Simón J.A.. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation and Cellular Therapy. May 2022. DOI: 10.1016/j.jtct.2022.01.026.
Impacto: 3.2. Cuartil: Q2
Prats-Martín C., Vargas M.T., Reinoso-Segura M., Caballero-Velázquez T., Martín-Chacón E., Morales-Camacho R.M.. The incidental detection of clonal haemopoiesis of indeterminate potential with del(5q). British Journal of Haematology. March 2022. DOI: 10.1111/bjh.18006.
Impacto: 6.5. Cuartil: Q1
Lara-Chica M., Correa-Sáez A., Jiménez-Izquierdo R., Garrido-Rodríguez M., Ponce F.J., Moreno R., Morrison K., Di Vona C., Arató K., Jiménez-Jiménez C., Morrugares R., Schmitz M.L., de la Luna S., de la Vega L., Calzado M.A.. A novel CDC25A/DYRK2 regulatory switch modulates cell cycle and survival. Cell Death and Differentiation. January 2022. DOI: 10.1038/s41418-021-00845-5.
Impacto: 12.4. Cuartil: Q1
(1er decil)
García-Guerrero E., Götz R., Doose S., Sauer M., Rodríguez-Gil A., Nerreter T., Kortüm K.M., Pérez-Simón J.A., Einsele H., Hudecek M., Danhof S.. Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab (Leukemia, (2021), 35, 1, (201-214), 10.1038/s41375-020-0840-y). Leukemia. January 2022. DOI: 10.1038/s41375-021-01355-6.
Impacto: 11.4. Cuartil: Q1
(1er decil)
Ramos T.L., García-Guerrero E., Caballero-Velázquez T., Rodríguez-Gil A., Caracuel-García R., Nufer M., Robles-Frías M.J., Barbado M.V., Pérez-Simón J.A.. Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease. Bone Marrow Transplantation. December 2021. DOI: 10.1038/s41409-021-01452-1.
Impacto: 5.174. Cuartil: Q2
Reguera-Ortega J.L., García-Guerrero E., Pérez-Simón J.A.. Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato. December 2021. DOI: 10.3390/hemato2040043.
Alcalde-Mellado P., Franco-Macías E., Morales-Camacho R.M., Caballero-Velázquez T., Rojas-Martínez J.A., Prats-Martín C.. Auer rod-like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia. British Journal of Haematology. September 2021. DOI: 10.1111/bjh.17512.
Impacto: 8.615. Cuartil: Q1
Paiva B., Vidriales M.B., Sempere A., Tarín F., Colado E., Benavente C., Cedena M.T., Sánchez J., Caballero-Velazquez T., Cordón L., Garces J.J., Simoes C., Martínez-Cuadrón D., Bernal T., Botella C., Grille S., Serrano J., Rodríguez-Medina C., Algarra L., Alonso-Domínguez J.M., Amigo M.L., Barrios M., García-Boyero R., Colorado M., Pérez-Oteyza J., Pérez-Encinas M., Costilla-Barriga L., Sayas M.J., Pérez O., González-Díaz M., Pérez-Simón J.A., Martínez-López J., Sossa C., Orfao A., San Miguel J.F., Sanz M.Á., Montesinos P.. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia. August 2021. DOI: 10.1038/s41375-021-01126-3.
Impacto: 12.883. Cuartil: Q1
(1er decil)
Chulián S., Martínez-Rubio Á., Pérez-García V.M., Rosa M., Goñi C.B., Gutiérrez J.F.R., Hermosín-Ramos L., Quintana Á.M., Caballero-Velázquez T., Ramírez-Orellana M., Robleda A.C., Fernández-Martínez J.L.. High-dimensional analysis of single-cell flow cytometry data predicts relapse in childhood acute lymphoblastic leukaemia. Cancers. January 2021. DOI: 10.3390/cancers13010017.
Impacto: 6.575. Cuartil: Q1
García-Guerrero E., Götz R., Doose S., Sauer M., Rodríguez-Gil A., Nerreter T., Kortüm K.M., Pérez-Simón J.A., Einsele H., Hudecek M., Danhof S.. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia. January 2021. DOI: 10.1038/s41375-020-0840-y.
Impacto: 12.883. Cuartil: Q1
(1er decil)
García-Guerrero E., Sierro-Martínez B., Pérez-Simón J.A.. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. Frontiers in Immunology. 5 June 2020. DOI: 10.3389/fimmu.2020.01128.
Impacto: 7.561. Cuartil: Q1
Prats-Martín C., Burillo-Sanz S., Morales-Camacho R.M., Pérez-López O., Suito M., Vargas M.T., Caballero-Velázquez T., Carrillo-Cruz E., González J., Bernal R., Pérez-Simón J.A.. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype. Cancer Medicine. 1 June 2020. DOI: 10.1002/cam4.2947.
Impacto: 4.452. Cuartil: Q2
Alvarez-Laderas I., Ramos T.L., Medrano M., Caracuel-García R., Barbado M.V., Sánchez-Hidalgo M., Zamora R., Alarcón-de-la-Lastra C., Hidalgo F.J., Piruat J.I., Caballero-Velázquez T., Pérez-Simón J.A.. Polyphenolic Extract (PE) from Olive Oil Exerts a Potent Immunomodulatory Effect and Prevents Graft-versus-Host Disease in a Mouse Model. Biology of Blood and Marrow Transplantation. April 2020. DOI: 10.1016/j.bbmt.2019.11.019.
Impacto: 5.742. Cuartil: Q1
Delgado-Serrano J., Morales-Camacho R.M., Caballero-Velázquez T., García-Canale S., Vargas M.T., Prats-Martín C.. Eosinophils engulfing platelets and with ring-shaped nuclei in nivolumab-associated eosinophilia. British Journal of Haematology. 1 March 2020. DOI: 10.1111/bjh.16376.
Impacto: 6.998. Cuartil: Q1
Escamilla Gómez V., García-Gutiérrez V., López Corral L., García Cadenas I., Pérez Martínez A., Márquez Malaver F.J., Caballero-Velázquez T., González Sierra P.A., Viguria Alegría M.C., Parra Salinas I.M., Calderón Cabrera C., González Vicent M., Rodríguez Torres N., Parody Porras R., Ferra Coll C., Orti G., Valcárcel Ferreiras D., De la Cámara LLanzá R., Molés P., Velázquez-Kennedy K., João Mende M., Caballero Barrigón D., Pérez E., Martino Bofarull R., Saavedra Gerosa S., Sierra J., Poch M., Zudaire Ripa M.T., Díaz Pérez M.A., Molina Angulo B., Sánchez Ortega I., Sanz Caballer J., Montoro Gómez J., Espigado Tocino I., Pérez-Simón J.A.. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplantation. 1 March 2020. DOI: 10.1038/s41409-019-0731-x.
Impacto: 5.483. Cuartil: Q1
Caballero-Velázquez T., Calderón-Cabrera C., López-Corral L., Puig N., Marquez-Malaver F., Pérez-López E., García-Calderón C., Rosso-Fernández C.M., Caballero Barrigón D., Martín J., Mateos M.V., San Miguel J., Pérez-Simón J.A.. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplantation. 1 February 2020. DOI: 10.1038/s41409-019-0670-6.
Impacto: 5.483. Cuartil: Q1
Sánchez-Céspedes J., Marrugal-Lorenzo J.A., Martín-Gandul C., Rodríguez-Torres N., Montero-Mateos E., Serna-Gallego A., Escamilla-Gómez V., Merino L., Espigado I., Pachón J., Simón J.A.P., Aguilar-Guisado M.. T-cells immune response controls the high incidence of adenovirus infection in adult allogenic hematopoietic transplantation recipients. Haematologica. 1 January 2020. DOI: 10.3324/HAEMATOL.2019.240101.
Impacto: 9.941. Cuartil: Q1
(1er decil)
Caeser R., Di Re M., Krupka J.A., Gao J., Lara-Chica M., Dias J.M.L., Cooke S.L., Fenner R., Usheva Z., Runge H.F.P., Beer P.A., Eldaly H., Pak H.K., Park C.S., Vassiliou G.S., Huntly B.J.P., Mupo A., Bashford-Rogers R.J.M., Hodson D.J.. Genetic modification of primary human B cells to model high-grade lymphoma. Nature Communications. 1 December 2019. DOI: 10.1038/s41467-019-12494-x.
Impacto: 12.121. Cuartil: Q1
(1er decil)
López-Corral L., Caballero-Velázquez T., López-Godino O., Rosiñol L., Pérez-Vicente S., Fernandez-Avilés F., Krsnik I., Morillo D., Heras I., Morgades M., Rifon J.J., Sampol A., Iniesta F., Ocio E.M., Martin J., Rovira M., Cabero M., Castilla-Llorente C., Ribera J.M., Torres-Juan M., Moraleda J.M., Martinez C., Vázquez A., Gutierrez G., Caballero D., San Miguel J.F., Mateos M.V., Pérez-Simón J.A.. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation. September 2019. DOI: 10.1016/j.bbmt.2019.04.026.
Impacto: 3.853. Cuartil: Q2
Carrillo-Cruz E., García-Lozano J.R., Marquez-Malaver F.J., Sanchez-Guijo F.M., Cuadrado I.M., Coll C.F., Valcarcel D., Lopez-Godino O., Cuesta M., Parody R., Lopez-Corral L., Alcoceba M., Caballero-Velazquez T., Rodríguez-Gil A., Bejarano-García J.A., Lopes Ramos T., Perez-Simon J.A.. Vitamin D modifies the incidence of graft-versus-host disease after allogeneic stem cell transplantation depending on the Vitamin D Receptor (VDR) polymorphisms. Clinical Cancer Research. 1 August 2019. DOI: 10.1158/1078-0432.CCR-18-3875.
Impacto: 10.107. Cuartil: Q1
(1er decil)
Romero-Ruiz A., Avendaño M.S., Dominguez F., Lozoya T., Molina-Abril H., Sangiao-Alvarellos S., Gurrea M., Lara-Chica M., Fernandez-Sanchez M., Torres-Jimenez E., Perdices-Lopez C., Abbara A., Steffani L., Calzado M.A., Dhillo W.S., Pellicer A., Tena-Sempere M.. Deregulation of miR-324/KISS1/kisspeptin in early ectopic pregnancy: mechanistic findings with clinical and diagnostic implications. American Journal of Obstetrics and Gynecology. May 2019. DOI: 10.1016/j.ajog.2019.01.228.
Impacto: 6.502. Cuartil: Q1
(1er decil)
Molinos-Quintana A., Trujillo-Hacha P., Piruat J.I., Bejarano-García J.A., García-Guerrero E., Pérez-Simón J.A., Muñoz M.. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists. Investigational New Drugs. 15 February 2019. DOI: 10.1007/s10637-018-0607-8.
Impacto: 3.525. Cuartil: Q2
Rodríguez-Arbolí E., Márquez-Malaver F.J., Rodríguez-Torres N., Caballero-Velázquez T., Escamilla-Gómez V., Calderón-Cabrera C., Falantes-González J.F., Solé-Rodríguez M., García-Ramírez P., Moya-Arnao M., Carreras E., Espigado-Tocino I., Pérez-Simón J.A.. Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval. Biology of Blood and Marrow Transplantation. January 2019. DOI: 10.1016/j.bbmt.2018.08.019.
Impacto: 3.853. Cuartil: Q2
Heras V., Sangiao-Alvarellos S., Manfredi-Lozano M., Sanchez-Tapia M.J., Ruiz-Pino F., Roa J., Lara-Chica M., Morrugares-Carmona R., Jouy N., Abreu A.P., Prevot V., Belsham D., Vazquez M.J., Calzado M.A., Pinilla L., Gaytan F., Latronico A.C., Kaiser U.B., Castellano J.M., Tena-Sempere M.. Hypothalamic miR-30 regulates puberty onset via repression of the puberty-suppressing factor, Mkrn3. PLoS Biology. 2019. DOI: 10.1371/journal.pbio.3000532.
Impacto: 7.076. Cuartil: Q1
(1er decil)
García-Calderón C.B., Bejarano-García J.A., Tinoco-Gago I., Castro M.J., Moreno-Gordillo P., Piruat J.I., Caballero-Velázquez T., Pérez-Simón J.A., Rosado I.V.. Genotoxicity of tetrahydrofolic acid to hematopoietic stem and progenitor cells. Cell Death and Differentiation. 1 November 2018. DOI: 10.1038/s41418-018-0089-4.
Impacto: 8.086. Cuartil: Q1
(1er decil)
Jiménez-Jiménez C., Lara-Chica M., Palomares B., Collado J.A., Lopez-Miranda J., Muñoz E., Calzado M.A.. Effect of N-acyl-dopamines on beta cell differentiation and wound healing in diabetic mice. Biochimica et Biophysica Acta - Molecular Cell Research. November 2018. DOI: 10.1016/j.bbamcr.2018.08.008.
Impacto: 4.739. Cuartil: Q1
Moreno P., Jiménez-Jiménez C., Garrido-Rodríguez M., Calderón-Santiago M., Molina S., Lara-Chica M., Priego-Capote F., Salvatierra Á., Muñoz E., Calzado M.A.. Metabolomic profiling of human lung tumor tissues – nucleotide metabolism as a candidate for therapeutic interventions and biomarkers. Molecular Oncology. October 2018. DOI: 10.1002/1878-0261.12369.
Impacto: 5.962. Cuartil: Q1
García-Guerrero E., Sánchez-Abarca L.I., Domingo E., Ramos T.L., Bejarano-García J.A., Gonzalez-Campos J.A., Caballero-Velázquez T., Pérez-Simón J.A.. Selection of tumor-specific cytotoxic T lymphocytes in acute myeloid leukemia patients through the identification of T-cells capable to establish stable interactions with the leukemic cells: "Doublet technology". Frontiers in Immunology. 3 September 2018. DOI: 10.3389/fimmu.2018.01971.
Impacto: 4.716. Cuartil: Q2
Matarraz S., Leoz P., Fernández C., Colado E., Chillón M.C., Vidriales M.B., González M., Rivera D., Osuna C.S., Caballero-Velázquez T., Van Der Velden V., Jongen-Lavrencic M., Gutiérrez O., Bermejo A.Y., Alonso L.G., García M.B., De Ramón Sánchez C., García-Donas G., Mateo A.G., Recio I., Sánchez-Real J., Mayado A., Gutiérrez M.L., Bárcena P., Barrena S., López A., Van Dongen J., Orfao A.. Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. Modern Pathology. 1 August 2018. DOI: 10.1038/s41379-018-0038-2.
Impacto: 6.365. Cuartil: Q1
(1er decil)
Afram G., Simón J.A.P., Remberger M., Caballero-Velázquez T., Martino R., Piñana J.L., Ringden O., Esquirol A., Lopez-Corral L., Garcia I., López-Godino O., Sierra J., Caballero D., Ljungman P., Vazquez L., Hägglund H.. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. Medical Oncology. 1 June 2018. DOI: 10.1007/s12032-018-1127-2.
Impacto: 3.252. Cuartil: Q2
Burillo-Sanz S., Morales-Camacho R.M., Caballero-Velázquez T., Carrillo E., Sánchez J., Pérez-López O., Pérez de Soto I., González Campos J., Prats-Martín C., Bernal R., Vargas M.T.. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3′ region mRNA expression. European Journal of Haematology. May 2018. DOI: 10.1111/ejh.13037.
Impacto: 2.217. Cuartil: Q3
Prats-Martín C., Jiménez-Guerrero P., Morales-Camacho R.M., Caballero-Velázquez T., Vargas M.T., Pérez O., Montero I., Falantes J., Burillo-Sanz S., Carrillo E., Borrero J.J., Bernal R., Pérez-Simón J.A.. KIT D816V− chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation. Annals of Hematology. 1 March 2018. DOI: 10.1007/s00277-017-3187-3.
Impacto: 2.85. Cuartil: Q3
Burillo-Sanz S., Vargas M.T., Morales-Camacho R.M., Caballero-Velázquez T., Sánchez J., García-Lozano J.R., Pérez de Soto I., Prats-Martín C., Bernal R., Pérez-Simón J.A.. RUNX1 amplification in AML with myelodysplasia-related changes and ring 21 chromosomes. Hematological Oncology. December 2017. DOI: 10.1002/hon.2287.
Impacto: 3.193. Cuartil: Q2
García-Guerrero E., Gogishvili T., Danhof S., Schreder M., Pallaud C., Pérez-Simón J.A., Einsele H., Hudecek M.. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood. 22 June 2017. DOI: 10.1182/blood-2017-03-770776.
Impacto: 15.132. Cuartil: Q1
(1er decil)
Barbado M.V., Medrano M., Caballero-Velázquez T., Álvarez-Laderas I., Sánchez-Abarca L.I., García-Guerrero E., Martín-Sánchez J., Rosado I.V., Piruat J.I., Gonzalez-Naranjo P., Campillo N.E., Páez J.A., Pérez-Simón J.A.. Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo. International Journal of Cancer. 1 February 2017. DOI: 10.1002/ijc.30483.
Impacto: 7.36. Cuartil: Q1
Caballero-Velazquez T., Montero I., Sanchez-Guijo F., Parody R., Saldana R., Valcarcel D., Lopez-Godino O., Coll C.F.I., Cuesta M., Carrillo-Vico A., Sanchez-Abarca L.I., Lopez-Corral L., Marquez-Malaver F.J., Perez-Simon J.A.. Immunomodulatory effect of Vitamin D after allogeneic stem cell transplantation: Results of a prospective multicenter clinical trial. Clinical Cancer Research. 1 December 2016. DOI: 10.1158/1078-0432.CCR-16-0238.
Impacto: 9.619. Cuartil: Q1
(1er decil)
García-Limones C., Lara-Chica M., Jiménez-Jiménez C., Pérez M., Moreno P., Muñoz E., Calzado M.A.. CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2. Oncogene. 18 August 2016. DOI: 10.1038/onc.2015.495.
Impacto: 7.519. Cuartil: Q1
(1er decil)
Morales-Camacho R.M., Caballero-Velázquez T., Prats-Martín C., Pérez-López O., Vargas M.T., Carrillo-Cruz E.. Haemophagocytosis by neoplastic cells in aleukaemic variant of mast cell leukaemia. British Journal of Haematology. 1 August 2016. DOI: 10.1111/bjh.14178.
Impacto: 5.67. Cuartil: Q1
Morales-Camacho R.M., Caballero-Velázquez T., Knight T., García A., Bernal R., Borrero J.J.. Leukaemic blast cannibalism in acute megakaryoblastic leukaemia with myeloid sarcoma. British Journal of Haematology. 1 May 2016. DOI: 10.1111/bjh.14002.
Impacto: 5.67. Cuartil: Q1
García-Guerrero E., Pérez-Simón J.A., Sánchez-Abarca L.I., Díaz-Moreno I., de la Rosa M.A., Díaz-Quintana A.. The dynamics of the human leukocyte antigen head domain modulates its recognition by the T-cell receptor. PLoS ONE. April 2016. DOI: 10.1371/journal.pone.0154219.
Impacto: 2.806. Cuartil: Q1
Burillo-Sanz S., Morales-Camacho R.M., Caballero-Velázquez T., Vargas M.T., García-Lozano J.R., Falantes J.F., Prats-Martín C., Bernal R., Pérez-Simón J.A.. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression. International Journal of Laboratory Hematology. 1 February 2016. DOI: 10.1111/ijlh.12435.
Impacto: 2.03. Cuartil: Q3
Bejarano-García J.A., Millán-Uclés Á., Rosado I.V., Sánchez-Abarca L.I., Caballero-Velázquez T., Durán-Galván M.J., Pérez-Simón J.A., Piruat J.I.. Sensitivity of hematopoietic stem cells to mitochondrial dysfunction by SdhD gene deletion. Cell Death and Disease. 2016. DOI: 10.1038/cddis.2016.411.
Impacto: 5.965. Cuartil: Q1
Oliva-Martin M.J., Sanchez-Abarca L.I., Rodhe J., Carrillo-Jimenez A., Vlachos P., Herrera A.J., Garcia-Quintanilla A., Caballero-Velazquez T., Perez-Simon J.A., Joseph B., Venero J.L.. Caspase-8 inhibition represses initial human monocyte activation in septic shock model. Oncotarget. 2016. DOI: 10.18632/oncotarget.9648.
Impacto: 5.168. Cuartil: Q1
García V., Lara-Chica M., Cantarero I., Sterner O., Calzado M.A., Muñoz E.. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. Oncotarget. 2016. DOI: 10.18632/oncotarget.6606.
Impacto: 5.168. Cuartil: Q1
Prats-Martín C., Morales-Camacho R.M., Blum-Domínguez M.A., Cabrera-Pérez R., Bernal R., Caballero-Velázquez T., Pérez-Simõn J.A.. Strong periodic acid-schiff reaction in hypervacuolated blastic plasmacytoid dendritic cell neoplasm. Diagnostic Cytopathology. 1 January 2016. DOI: 10.1002/dc.23372.
Impacto: 1.161. Cuartil: Q4
Moreno P., Lara-Chica M., Soler-Torronteras R., Caro T., Medina M., Álvarez A., Salvatierra Á., Muñoz E., Calzado M.A.. The expression of the ubiquitin ligase SIAH2 (seven In Absentia Homolog 2) is increased in human lung cancer. PLoS ONE. 1 November 2015. DOI: 10.1371/journal.pone.0143376.
Impacto: 3.057. Cuartil: Q1
Vargas M.T., Escamilla V., Morales-Camacho R.M., Prats C., Caballero-Velázquez T., Bernal R., Pérez Simón J.A.. Multiple pseudo-chediak-higashi inclusions associated with MYC deletion in a patient with acute myeloid leukemia. Acta Haematologica. 22 May 2015. DOI: 10.1159/000366095.
Impacto: 1.053. Cuartil: Q4
Báez A., Álvarez-Laderas I., Piruat J.I., Caballero-Veiazquez T., Victoria Barbado M., Mimn-Ucles A., Medrano M., García-Guerrero E., Sanchez-Abarca L.I., Perez-Simón J.A.. The CD27<sup>+</sup> memory B cells display changes in the gene expression pattern in elderly individuals. Immunology. March 2015. DOI: 10.1111/IMM.12381.
Impacto: 4.078. Cuartil: Q2
Caballero F.J., Soler-Torronteras R., Lara-Chica M., García V., Fiebich B.L., Muñoz E., Calzado M.A.. AM404 inhibits NFAT and NF-κB signaling pathways and impairs migration and invasiveness of neuroblastoma cells. European Journal of Pharmacology. 5 January 2015. DOI: 10.1016/j.ejphar.2014.11.023.
Impacto: 2.73. Cuartil: Q2
Báez A., Piruat J.I., Caballero-Velázquez T., Sánchez-Abarca L.I., Álvarez-Laderas I., Victoria Barbado M., García-Guerrero E., Millán-Uclés Á., Martín-Sánchez J., Medrano M., Pérez-Simón J.A.. Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells. American Journal of Cancer Research. 2015. DOI: .
Impacto: 3.425. Cuartil: Q2
Sánchez-Abarca L.I., Hernández-Galilea E., Lorenzo R., Herrero C., Velasco A., Carrancio S., Caballero-Velázquez T., Rodríguez-Barbosa J.I., Parrilla M., Cañizo C.D., Miguel J.S., Aijón J., Pérez-Simón J.A.. Human bone marrow stromal cells differentiate into corneal tissue and prevent ocular graft-versus-host disease in mice. Cell Transplantation. 2015. DOI: 10.3727/096368915X687480.
Impacto: 3.427. Cuartil: Q2
Parody R., Lopez-Corral L., Godino O.L., Cadenas I.G., Martinez A.P., Vazquez L., Martino R., Martinez C., Solano C., Barba P., Valcarcel D., Caballero-Velazquez T., Marquez-Malaver F.J., Sierra J., Caballero D., Perez-Simón J.A.. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. Bone Marrow Transplantation. 10 January 2015. DOI: 10.1038/bmt.2014.220.
Impacto: 3.636. Cuartil: Q2
Sánchez-Guijo F., Caballero-Velázquez T., López-Villar O., Redondo A., Parody R., Martínez C., Olavarría E., Andreu E., Prósper F., Díez-Campelo M., Regidor C., Villaron E., López-Corral L., Caballero D., Cañizo M.C.d., Pérez-Simon J.A.. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 1 October 2014. DOI: 10.1016/j.bbmt.2014.06.015.
Impacto: 3.404. Cuartil: Q2
Paiva B., Chandia M., Vidriales M.B., Colado E., Caballero-Velázquez T., Escalante F., Garcia De Coca A., Montes M.C., Garcia-Sanz R., Ocio E.M., Mateos M.V., San Miguel J.F.. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma. Blood. 21 August 2014. DOI: 10.1182/blood-2014-04-567909.
Impacto: 10.452. Cuartil: Q1
(1er decil)
Soler-Torronteras R., Lara-Chica M., García V., Calzado M.A., Muñoz E.. Hypoximimetic activity of N-acyl-dopamines. N-arachidonoyl-dopamine stabilizes HIF-1α protein through a SIAH2-dependent pathway. Biochimica et Biophysica Acta - Molecular Cell Research. November 2014. DOI: 10.1016/j.bbamcr.2014.07.005.
Impacto: 5.019. Cuartil: Q1
Calderón-Cabrera C., Montero I., Morales R.M., Sánchez J., Carrillo E., Caballero-Velázquez T., Prats C., Bernal R., De Blas J.M., Pérez-Simón J.A.. Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis. Leukemia Research Reports. 2013. DOI: 10.1016/j.lrr.2013.08.001.
Caballero-Velázquez T., López-Corral L., Encinas C., Castilla-Llorente C., Martino R., Rosiñol L., Sampol A., Caballero D., Serrano D., Heras I., San Miguel J., Pérez-Simón J.A.. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. British Journal of Haematology. August 2013. DOI: 10.1111/bjh.12410.
Impacto: 4.959. Cuartil: Q1
Sánchez-Abarca L.I., Álvarez-Laderas I., Díez Campelo M., Caballero-Velázquez T., Herrero C., Muntión S., Calderón C., García-Guerrero E., Sánchez-Guijo F., Del Cañizo C., San Miguel J., Pérez-Simón J.A.. Uptake and delivery of antigens by mesenchymal stromal cells. Cytotherapy. June 2013. DOI: 10.1016/j.jcyt.2013.01.216.
Impacto: 3.1. Cuartil: Q2
Pérez-Simón J.A., Afram G., Martino R., Piñana J.L., Caballero-Velazquez T., Ringden O., Valcarcel D., Caballero D., Remberger M., de Paz Y., Sierra J., Miguel J.S., Hagglund H.. Evaluation of prognostic factors among patients with chronic graft-versus-host disease. Haematologica. 1 August 2012. DOI: 10.3324/haematol.2011.055244.
Impacto: 5.935. Cuartil: Q1
Gutierrez-Cosío S., de la Rica L., Ballestar E., Santamaría C., Sánchez-Abarca L.I., Caballero-Velazquez T., Blanco B., Calderón C., Herrero-Sánchez C., Carrancio S., Ciudad L., Cañizo C., Miguel J.F.S., Pérez-Simón J.A.. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: Effect of 5-AZA treatment. Leukemia Research. July 2012. DOI: 10.1016/j.leukres.2012.02.030.
Impacto: 2.764. Cuartil: Q2
Caballero-Velázquez T., Sánchez-Abarca L.I., Gutierrez-Cosio S., Blanco B., Calderon C., Herrero C., Carrancio S., Serrano C., del Cañizo C., San Miguel J.F., Pérez-Simón J.A.. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. Haematologica. 20120901. DOI: 10.3324/haematol.2011.058677.
Impacto: 5.935. Cuartil: Q1
Silva F., Pérez-Simón J.A., Caballero-Velazquez T., Sánchez-Guijo F.M., Villanueva-Gomez F., Vazquez L., Del Cañizo C., Caballero D., San Miguel J.. Effect of vitamin D treatment in chronic GVHD. Bone Marrow Transplantation. October 2011. DOI: 10.1038/bmt.2010.317.
Impacto: 3.746. Cuartil: Q2
Blanco B., Sánchez-Abarca L.I., Caballero-Velázquez T., Santamaría C., Inogés S., Pérez-Simón J.A.. Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens. Leukemia Research. October 2011. DOI: 10.1016/j.leukres.2011.05.018.
Impacto: 2.923. Cuartil: Q2
Rodríguez-Muñoz M., De La Torre-Madrid E., Sánchez-Blázquez P., Garzón J.. NO-released zinc supports the simultaneous binding of Raf-1 and PKCγ cysteine-rich domains to HINT1 protein at the mu-opioid receptor. Antioxidants and Redox Signaling. 15 June 2011. DOI: 10.1089/ars.2010.3511.
Impacto: 8.456. Cuartil: Q1
(1er decil)
Velasco Guardado A., López-Corral L., Pérez-Simón J.A., Caballero-Velázquez T., Flores Corral T., Caballero Barrigón D., Rodríguez Pérez A.. Helicobacter pylori Infection and Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. May 2011. DOI: 10.1016/j.bbmt.2010.11.014.
Impacto: 3.873. Cuartil: Q1
Pérez R.L., Pérez-Simón J.A., Caballero-Velazquez T., Flores T., Carrancio S., Herrero C., Blanco B., Gutierrez-Cosio S., Cañete-Campos C., Cruz González F., San-Miguel J.F., Hernández-Galilea E., Sánchez-Abarca I.. Limbus Damage in Ocular Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. February 2011. DOI: 10.1016/j.bbmt.2010.08.008.
Impacto: 3.873. Cuartil: Q1
Caballero Velázquez T., Pérez Simón J.A.. Chronic graft-versus-host disease. Methods and Findings in Experimental and Clinical Pharmacology. 2010. DOI: .
Impacto: 1.037. Cuartil: Q4
Sánchez-Abarca L.I., Gutierrez-Cosio S., Santamaría C., Caballero-Velazquez T., Blanco B., Herrero-Sánchez C., García J.L., Carrancio S., Hernández-Campo P., González F.J., Flores T., Ciudad L., Ballestar E., Del Cañizo C., San Miguel J.F., Pérez-Simon J.A.. Immunomodulatory effect of 5-azacytidine (5-azaC): Potential role in the transplantation setting. Blood. 7 January 2010. DOI: 10.1182/blood-2009-03-210393.
Impacto: 10.558. Cuartil: Q1
(1er decil)
Villanueva F.N., Pérez-Simón J.A., Silva F.F., Caballero-Velázquez T.T., Sánchez-Guijo F.F., Cañizo C.C., Vázquez L.L., Caballero D.D., San Miguel J.F.. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. October 2009. DOI: 10.1016/j.bbmt.2009.05.018.
Impacto: 3.149. Cuartil: Q2
Blanco B., Pérez-Simón J.A., Sánchez-Abarca L.I., Caballero-Velazquez T., Gutierrez-Cossío S., Hernández-Campo P., Díez-Campelo M., Herrero-Sanchez C., Rodriguez-Serrano C., Santamaría C., Sánchez-Guijo F.M., Del Cañizo C., San Miguel J.F.. Treatment with bortezomib of human CD4<sup>+</sup> T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica. July 2009. DOI: 10.3324/haematol.2008.005017.
Impacto: 6.416. Cuartil: Q1
Garzón J., de la Torre-Madrid E., Rodríguez-Muñoz M., Vicente-Sánchez A., Sánchez-Blázquez P.. Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. Molecular Pain. 10 March 2009. DOI: 10.1186/1744-8069-5-11.
Impacto: 4.187. Cuartil: Q1
Sánchez-Blázquez P., Rodríguez-Muñoz M., de la Torre-Madrid E., Garzón J.. Brain-specific Gαz interacts with Src tyrosine kinase to regulate Mu-opioid receptor-NMDAR signaling pathway. Cellular Signalling. September 2009. DOI: 10.1016/j.cellsig.2009.05.003.
Impacto: 4.094. Cuartil: Q2
Rodríguez-Muñoz M., de la Torre-Madrid E., Sánchez-Blázquez P., Wang J.B., Garzón J.. NMDAR-nNOS generated zinc recruits PKCγ to the HINT1-RGS17 complex bound to the C terminus of Mu-opioid receptors. Cellular Signalling. October 2008. DOI: 10.1016/j.cellsig.2008.06.015.
Impacto: 4.305. Cuartil: Q2
Sánchez-Blázquez P., Rodríguez-Muñoz M., Montero C., de la Torre-Madrid E., Garzón J.. Calcium/calmodulin-dependent protein kinase II supports morphine antinociceptive tolerance by phosphorylation of glycosylated phosducin-like protein. Neuropharmacology. February 2008. DOI: 10.1016/j.neuropharm.2007.10.002.
Impacto: 3.383. Cuartil: Q2
Rodríguez-Muñoz M., de la Torre-Madrid E., Gaitán G., Sánchez-Blázquez P., Garzón J.. RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons. Cellular Signalling. December 2007. DOI: 10.1016/j.cellsig.2007.08.003.
Impacto: 4.147. Cuartil: N/D
Rodríguez-Muñoz M., de la Torre-Madrid E., Sánchez-Blázquez P., Garzón J.. Morphine induces endocytosis of neuronal μ-opioid receptors through the sustained transfer of Gα subunits to RGSZ2 proteins. Molecular Pain. 17 July 2007. DOI: 10.1186/1744-8069-3-19.
Impacto: 4.127. Cuartil: N/D
Garzón J., Rodríguez-Muñoz M., De La Torre-Madrid E., Sánchez-Blázquez P.. Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS. Psychopharmacology. June 2005. DOI: 10.1007/s00213-005-2248-9.
Impacto: 3.994. Cuartil: N/D